Marina Baretti

Marina Baretti

Oncology

201 North Broadway Street, Viragh BLDG 5th FL
Viragh BLDG 5th FL
Baltimore, MD 21287

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 60 publications

Baseline and dynamic cytokines as biomarkers for immune checkpoint and anti-VEGF therapy in advanced hepatocellular carcinoma.

Baseline and dynamic cytokines as biomarkers for immune checkpoint and anti-VEGF therapy in advanced hepatocellular carcinoma.

Journal: ESMO gastrointestinal oncology

Published: April 17, 2026

Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial.

Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial.

Journal: Nature communications

Published: April 15, 2026

Clinical and molecular response to vorasidenib in post-transplant patient with IDH2-mutant intrahepatic cholangiocarcinoma.

Clinical and molecular response to vorasidenib in post-transplant patient with IDH2-mutant intrahepatic cholangiocarcinoma.

Journal: The oncologist

Published: April 09, 2026

First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts.

First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts.

Journal: Cancer discovery

Published: December 31, 2025

Peripheral Th17 immune signature associates with excellent response to anti-PD1/anti-PD-L1 therapy across solid tumors.

Peripheral Th17 immune signature associates with excellent response to anti-PD1/anti-PD-L1 therapy across solid tumors.

Journal: Cancer immunology research

Published: December 17, 2025

Serum Procalcitonin: A Novel Tumor Biomarker for Diagnosis and Follow-Up in Fibrolamellar Hepatocellular Carcinoma.

Serum Procalcitonin: A Novel Tumor Biomarker for Diagnosis and Follow-Up in Fibrolamellar Hepatocellular Carcinoma.

Journal: medRxiv : the preprint server for health sciences

Published: December 03, 2025

Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial.

Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial.

Journal: Nature communications

Published: December 02, 2025

Serum procalcitonin: A novel tumor biomarker for diagnosis and disease monitoring in fibrolamellar hepatocellular carcinoma.

Serum procalcitonin: A novel tumor biomarker for diagnosis and disease monitoring in fibrolamellar hepatocellular carcinoma.

Journal: Journal of hepatology

Published: October 15, 2025

Clinical guideline for the diagnosis and treatment of fibrolamellar carcinoma.

Clinical guideline for the diagnosis and treatment of fibrolamellar carcinoma.

Journal: Hepatology (Baltimore, Md.)

Published: September 02, 2025

Outcomes of Hepatocellular Carcinoma involving the Portal Vein Main Trunk and/or the Inferior Vena Cava: Experience From a Multidisciplinary Liver Cancer Clinic.

Outcomes of Hepatocellular Carcinoma involving the Portal Vein Main Trunk and/or the Inferior Vena Cava: Experience From a Multidisciplinary Liver Cancer Clinic.

Journal: Cancer medicine

Published: August 09, 2025

Profiling ADC targets in cholangiocarcinoma: implications for therapeutic development.

Profiling ADC targets in cholangiocarcinoma: implications for therapeutic development.

Journal: NPJ precision oncology

Published: July 18, 2025

Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial.

Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial.

Journal: Nature communications

Published: June 25, 2025

Showing 1-12 of 60

Last Updated: 09/26/2026